Results 81 to 90 of about 9,011 (201)

Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients

ESC Heart Failure, 2022
Aims Routine, intermittent inotropic therapy (IIT) is still applied in advanced heart failure (HF) patients either as a bridge to definitive treatment or as a mean to improve quality of life (QOL), despite limited evidence to support its' use.
Assi Milwidsky, Shir Frydman, Michal Laufer‐Perl, Ben Sadeh, Orly Sapir, Yoav Granot, Aviram Hochstadt, Liuba Korotetski, Liora Ketchker, Yan Topilsky, Shmuel Banai, Ofer Havakuk   +11 more
doaj   +1 more source

Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome

Clinical Cardiology, Volume 48, Issue 12, December 2025.
The CYP3A5 rs776746 CC genotype is a strong biomarker for ticagrelor‐induced dyspnea, conferring a 2.3‐fold higher risk. Genotype‐guided antiplatelet therapy may mitigate this adverse reaction, enabling personalized treatment for ACS patients. ABSTRACT Background Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with
Yanming Zhang, Gaoxiu Yu, Cong Wang, Jingwen Song, Junmei Liu, Feng Chen   +5 more
wiley   +1 more source

European experience on the practical use of levosimendan in patients with acute heart failure syndromes [PDF]

, 2005
The novel calcium sensitizer and ATP-dependent potassium channel opener levosimendan has been introduced for routine use in several European countries. Recent reports on clinical experience confirm the positive hemodynamic results and beneficial clinical
Cardoso, JS, Follath, F, Franco, F
core   +1 more source

Nurse‐coordinated multidisciplinary comprehensive heart failure management programme: A propensity‐matched trial

ESC Heart Failure, Volume 12, Issue 6, Page 4160-4170, December 2025.
Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan, Polly Wai‐Chi Li, Derek Pok‐Him Lee, Esmond Yan‐Hang Fong, Ivy Sin‐Yee Ng, Samantha Ki‐Man Chiu, Clara Woon‐Shan Fok, Frederick Kin‐Wa Li, Shirley Ka‐Wai Lee, Karen K. Y. Ho, Wilson Y. S. Leung, Cathy Cheuk‐Sum Chan, Cindy Yiu‐Ning Tsang, Michael Kang‐Yin Lee   +13 more
wiley   +1 more source

The therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction

Journal of International Medical Research
Objective To explore the therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction. Method Patients with prolonged ventilator weaning and cardiac dysfunction were randomly allocated to receive conventional ...
Fang Xiong, Zongjun Hu, Chao Liu, Kexiang Zhang, Qilong Zhou, Jianguo Chen, Hua Lu, Xi Yue, Jianxin Zhao, Pengfei Pan   +9 more
doaj   +1 more source

Worsening versus advanced heart failure: Management and challenges

ESC Heart Failure, Volume 12, Issue 6, Page 3856-3868, December 2025.
Clinical feature, circulating biomarkers and therapeutic management of patients with WHF versus AdvHF. Abbreviations: AdvHF, advanced heart failure; HF, heart failure; HTx, heart transplant; GDMT, guideline‐directed medical therapy; MCS, mechanical circulatory support; NYHA, New York Heart Association; WHF, worsening heart failure.
Alberto Palazzuoli, Marco Giuseppe Del Buono, Giulia La Vecchia, Stephen J. Greene, Andrew P. Ambrosy, Ovidiu Chioncel, Finn Gustafsson, Selim R. Krim, Carl J. Lavie, Marianna Adamo, Tuvia Ben Gal, Oliviana Geavlete, Laura Antohi, Giuseppe Rosano, Sean Collins, Filippo Crea   +15 more
wiley   +1 more source

Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION‐HEART multicentre randomised trial [PDF]

, 2018
[Abstract] Aims. The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with ...
Altenberger, Aversa, Cleland, Comín-Colet, Comín-Colet, Farré, Iqbal, Kleber, Mebazaa, Mentz, Metra, Nieminen, Nieminen, Packer, Papp, Pollesello, Solomon, Thackray, Young   +18 more
core   +5 more sources

Haemodynamic effects of istaroxime in SCAI stage B HF‐related cardiogenic shock: Insights from the SEISMiC trial

ESC Heart Failure, Volume 12, Issue 6, Page 3966-3975, December 2025.
Among patients with ADHF‐related SCAI stage B CS enrolled in SEISMiC, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in aortic pulsatility index and LV stroke work index, and with increase of PA compliance and reduction in PA elastance at 48 h.
Matteo Pagnesi, Gad Cotter, Beth Davison, Daniel Burkhoff, Alexander Mebazaa, Jan Biegus, Ovidiu Chioncel, Christopher Edwards, Koji Takagi, Gerasimos Filippatos, Agnieszka Tycińska, Maria Novosadova, Gaurav Gulati, Marianela Barros, Maria Luz Diaz, Carlos Guardia, Robert Zymliński, Piotr Gajewski, Piotr Ponikowski, Phillip Simmons, Steven Simonson, Marco Metra   +21 more
wiley   +1 more source

Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT

Efficacy and Mechanism Evaluation, 2018
Background: In septic shock, cardiovascular resuscitation using catecholamine vasopressors and inotropes is standard therapy, but catecholamines have important side effects.
Anthony C Gordon, Shalini Santhakumaran, Farah Al-Beidh, Robert ML Orme, Gavin D Perkins, Mervyn Singer, Daniel F McAuley, Alexina J Mason, Josie K Ward, Kieran P O’Dea, Timothy Felton, Mary Cross, Janis Best-Lane, Jonas Lexow, Ashley Campbell, Deborah Ashby   +15 more
doaj   +1 more source

Practical approach to diastolic dysfunction in light of the new guidelines and clinical applications in the operating room and in the intensive care [PDF]

, 2018
There is growing evidence both in the perioperative period and in the field of intensive care (ICU) on the association between left ventricular diastolic dysfunction (LVDD) and worse outcomes in patients.
Morelli, A., Sanfilippo, F., Scolletta, S., Vieillard-Baron, A.   +3 more
core   +1 more source